ImmunityBio and Oncolytics Biotech Propel Cancer Treatment Forward with GOBLET Study Advances
- Oncolytics Biotech's GOBLET study incorporates U.S. sites to expedite enrollment for challenging cancers like pancreatic cancer.
- Preliminary data from GOBLET shows pelareorep achieving a 62% objective response rate in treating metastatic pancreatic cancer.
- Oncolytics Biotech's partnerships enhance research capabilities, positioning the company as a leader in innovative cancer therapies.
Oncolytics Biotech Advances Cancer Treatment with GOBLET Study
Oncolytics Biotech Inc. is at the forefront of innovation in cancer treatment, particularly through its immunotherapy, pelareorep. The company is leveraging the momentum created by the FDA's accelerated approval of two new cancer therapies in August 2025 to enhance its presence in the oncology sector. With the GOBLET study now incorporating U.S. clinical sites, including Northwestern University, Oncolytics Biotech aims to expedite patient enrollment for difficult-to-treat cancers such as pancreatic cancer. This initiative is crucial, as pancreatic cancer remains one of the most challenging malignancies to treat effectively. CEO Jared Kelly emphasizes the necessity of utilizing clinical data to provide regulatory clarity for pelareorep, which is positioned as a platform immunotherapy specifically targeting gastrointestinal tumors, where treatment options are critically limited.
The GOBLET study has already yielded encouraging results, particularly with a 33% overall response rate observed in patients suffering from second-line squamous cell carcinoma of the anal canal. This figure notably exceeds the response rates of existing treatment modalities, highlighting pelareorep's potential as a game-changer in oncology. With 20 evaluable patients currently enrolled, the study is on track for completion by the end of 2025, with an efficacy update expected in Q4 2025. Such advancements not only signify progress in the fight against cancer but also reinforce Oncolytics Biotech's commitment to addressing unmet medical needs in the oncology landscape.
Cohort 5 of the GOBLET study represents a particularly critical component of Oncolytics Biotech's research, as it evaluates pelareorep in combination with chemotherapy and checkpoint inhibitors for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Preliminary data suggests a remarkable 62% objective response rate in 13 evaluable patients, which could revolutionize treatment protocols for this aggressive cancer type. With 40% of the target 60 patients enrolled, full enrollment is anticipated by the end of 2026, with interim overall survival data expected in Q1 2026. As the cancer immunotherapy market is projected to reach $258.22 billion by 2031, Oncolytics Biotech is well-positioned to capitalize on this growth through its innovative and promising treatment strategies.
In addition to its clinical advancements, Oncolytics Biotech's strategic partnerships and collaboration with prominent research institutions further bolster its position in the competitive oncology market. By aligning with leading experts and institutions, the company enhances its research capabilities and accelerates the development of its groundbreaking therapies. As the landscape of cancer treatment continues to evolve, Oncolytics Biotech's commitment to innovation remains unwavering, positioning it as a key player in the future of cancer care.